Theravance Q1 net loss narrows to $4.9M; YUPELRI revenue up 15%; all generic litigation settled

Theravance Biopharma, Inc.

2026-Q1 EPS reported -$0.10 revenue$17,699,000

YUPELRI collaboration revenue of $17.7M, up 15% YoY; implied 35% share of net sales $21.9M (+7%).
Net loss $4.9M vs. $13.6M YoY; Non-GAAP net income from operations $0.6M vs. loss of $8.6M.
Operating expenses down ~20% YoY (ex-restructuring); restructuring on track for ~60% reduction by Q3 2026.
All Hatch-Waxman YUPELRI litigation resolved; settlement with Mankind Pharma sets licensed launch date April 23, 2039.
Cash $395M, no debt; Strategic Review Committee evaluating sale or other value-maximizing alternatives.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Theravance Biopharma, Inc. reported first quarter of 2026 results: revenue $17.7 million.

Period: first quarter of 2026
Revenue: $17.7 million
Result: reported results

Exact text from the filing

Total revenue for the first quarter of 2026 was $17.7 million, consisting entirely of Viatris collaboration revenue.

View on SEC.gov

Browse all earnings releases →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-056733

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.